## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.04 indicates fundamental undervaluation. Caution: momentum weakening (-8.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($320.71)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 2)

**1. Osaic Holdings Inc. Grows Stock Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251219T103422 | Bullish | Relevance: 100%
- Osaic Holdings Inc. significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) by 21.1% in the second quarter, bringing its total holdings to 45,405 shares valued at approximately $17.68 million. This move is mirrored by other major institutional investors like Vanguard Group, Sanders Capital, and Norges Bank, indicating strong institutional confidence in the company. Elevance Health has a "Moderate Buy" consensus rating from analysts, with a target price of $400.44, and recently reported beating EPS estimates and declared a quarterly dividend.

**2. Wall Street Sees an 18% Upside to Elevance Health (ELV)**
- Source: Insider Monkey | 20251217T132021 | Bullish | Relevance: 100%
- Elevance Health (ELV) is seen by Wall Street as having an 18% upside, with analysts like TD Cowen reiterating a Buy recommendation and raising the price target to $400. CEO Seth Klarman holds a substantial stake in the company. Despite some challenges, Elevance Health's Q3 2025 results showed strong operating revenue and adjusted diluted EPS growth.

**3. UnitedHealth, Elevance, Aetna tops in insurance market share: AMA**
- Source: Modern Healthcare | 20251217T110821 | Bullish | Relevance: 100%
- According to the American Medical Association, UnitedHealth Group, Elevance Health, and Blue Cross Blue Shield of Michigan are among the top ten in health insurance market share for 2024. The article highlights the dominant positions of these major insurers.

**4. Deutsche Bank Downgrades Elevance Health to Hold From Buy, Adjusts Price Target to $320 From $332**
- Source: marketscreener.com | 20251219T130810 | Bearish | Relevance: 100%
- Deutsche Bank has downgraded Elevance Health (ELV) from Buy to Hold and adjusted its price target from $332 to $320. This change reflects a revised outlook on the healthcare provider's stock. The article also provides recent news and analyst ratings for Elevance Health from other financial institutions.

**5. Elevance Health, Inc. $ELV Shares Sold by Thrivent Financial for Lutherans**
- Source: MarketBeat | 20251219T103422 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly reduced its stake in Elevance Health (NYSE:ELV) by 16.2% in Q2, selling 3,422 shares; the institution now holds 17,693 shares valued at approximately $6.87 million. Despite this, analyst sentiment remains a "Moderate Buy" with an average price target of $400.44 after the company surpassed Q3 earnings expectations with $6.03 EPS and $50.09 billion revenue, and declared a quarterly dividend of $1.71. Elevance Health's stock performance shows a 1-year low of $273.71 and a 1-year high of $458.75, with ongoing institutional interest from other hedge funds like Aspen Investment Management Inc and Regatta Capital Group LLC.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.04 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $76.7B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.04 |
| Forward P/E | 12.6 |
| Current P/E | 11.4 |
| YoY Growth | -10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.5% to 0.2% (-8.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >4.0% for momentum thesis). MRS_5 (-3.5%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 52. Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.24% (CS: 55) | Neutral |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | 0.46 | Bullish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 0.955x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $340.37
- **Stop Loss:** $320.71 (5.8% risk)
- **Target:** $379.69 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $20,762.57
- **Portfolio %:** 20.76%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*